Efficacy of Extracorporeal Shock Wave Therapy on Spasticity

NCT ID: NCT06225024

Last Updated: 2024-02-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-15

Study Completion Date

2023-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Introduction: We aimed to compare the efficacy of Botulinum Toxin Type A(BoNT-A) injection and BoNT-A injection in combination with ESWT for post-stroke lower extremity ankle plantar flexor spasticity.

Materials and Method: Patients with post-stroke ankle plantar flexor spasticity of 1 or more on the modified Ashworth Scale(MAS) were randomized into two groups.

Group 1(n:20): BoNT-A was injected into the gastrocnemius muscle and conventional physical therapy exercises were performed.

Group 2(n:20): ESWT was applied to the gastrocnemius muscle in addition to the treatments in group 1.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Group 1 (n:20): BoNT-A was injected into the affected gastrocnemius muscle under ultrasonography guidance at doses recommended by standard guidelines and appropriate for the patient (50 IU to the medial head, 25 IU to the lateral head). In addition, conventional physical therapy exercises (stretching exercises, range of motion (ROM) exercises, neurophysiologic exercises, and gait exercises) were applied to the patients five days a week for four weeks.

Group 2 (n:20): In addition to the treatments (BoNT-A injection and exercise) in Group 1, one week after the injection, a total of 4 sessions (2 days a week) of ESWT (1000 impulses with an energy density of 0.1 mj/mm2, pressure of 2 bar, and frequency of 4 Hz) were applied to the medial and lateral heads of the gastrocnemius muscle.

The patients in both groups underwent the following evaluations before treatment, at one month and three months after treatment by a treatment-blinded Physical Medicine and Rehabilitation (PMR) physician.

Patients' age, sex, occupation, hemiplegic sides, and etiology of hemiplegia were recorded. Physical examination was performed, and examination findings were recorded. The presence of post-treatment pain, redness, tenderness, or other adverse findings were questioned.

MAS, Brunnstrom Motor Recovery Stage(BMRS), ankle range of motion(ROM) measurement, clonus score(CS), Barthel Index(BI), Heckmatt measurements with ultrasonography, and visual analog scale(VAS) evaluations were performed on the patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Spasticity, Muscle

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized Controlled
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
The patients in both groups underwent the following evaluations before treatment, at one month and three months after treatment by a treatment-blinded Physical Medicine and Rehabilitation (PMR) physician:

1. Modified Ashworth Scale (MAS)
2. Brunnstrom Motor Recovery Stage (BMRS)
3. Ankle range of motion (2) measurement
4. Clonus score (CS)
5. Barthel Index (BI)
6. Heckmatt measurements with ultrasonography
7. Visual analog scale (VAS) pain assessment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BoNT-A

BoNT-A was injected into the affected gastrocnemius muscle under ultrasonography guidance at doses recommended by standard guidelines and appropriate for the patient (50 IU to the medial head, 25 IU to the lateral head). In addition, conventional physical therapy exercises (stretching exercises, range of motion (ROM) exercises, neurophysiologic exercises, and gait exercises) were applied to the patients five days a week for four weeks.

Group Type ACTIVE_COMPARATOR

BoNT A

Intervention Type DRUG

BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management

BoNT-A and ESWT

In addition to the treatments (BoNT-A injection and exercise) in Group 1, one week after the injection, a total of 4 sessions (2 days a week) of ESWT (1000 impulses with an energy density of 0.1 mj/mm2, pressure of 2 bar, and frequency of 4 Hz) were applied to the medial and lateral heads of the gastrocnemius muscle.

Group Type EXPERIMENTAL

ESWT

Intervention Type DEVICE

Extracorporeal shock wave therapy (ESWT) is a treatment method based on high-intensity sound waves focusing on the desired body area to provide treatment. ESWT is a safe, non-invasive, alternative treatment for spasticity in patients with stroke, cerebral palsy, and multiple sclerosis and does not cause muscle weakness or adverse effects

BoNT A

Intervention Type DRUG

BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ESWT

Extracorporeal shock wave therapy (ESWT) is a treatment method based on high-intensity sound waves focusing on the desired body area to provide treatment. ESWT is a safe, non-invasive, alternative treatment for spasticity in patients with stroke, cerebral palsy, and multiple sclerosis and does not cause muscle weakness or adverse effects

Intervention Type DEVICE

BoNT A

BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

device therapy drug therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Being diagnosed with stroke according to the definition of the World Health Organization in 1989
* Having a stroke confirmed by computed tomography (CT) and magnetic resonance imaging (MRI)
* Being aged over 18 years
* Having a MAS score of 1 and above for gastrocnemius, the plantar flexor muscle of the ankle
* Having a stable general condition after a stroke
* Giving consent to participate in the study.

Exclusion Criteria

* Having a fixed contracture in the ankle
* Having no spasticity in the soleus, the plantar flexor muscle of the ankle
* Previous antispastic surgery performed on the area
* Change in antispastic drug use in the last six months, if any
* Injection of BoNT-A, alcohol, phenol, or any other substance into the area in the last six months
* Active infection or cancer at the application site
* Having a cardiac pacemaker
* Having bleeding diathesis
* Having vascular complaints such as deep vein thrombosis, venous stasis, phlebitis, arterial disease
* Being pregnant
* Having neuromuscular junction disease or motor neuron disease
* Having a known allergy to BoNT-A
* 12\. Active use of aminoglycosides or other antibiotic groups.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Saglik Bilimleri Universitesi

OTHER

Sponsor Role collaborator

Kayseri City Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Havva Talay Çalış

Prof

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

HAVVA TALAY ÇALIŞ

Role: PRINCIPAL_INVESTIGATOR

KAYSERİ CITY HOSPITAL

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Health Sciences University, Kayseri Medicine Faculty

Kayseri, Kocasinan, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Yoldas Aslan S, Kutlay S, Dusunceli Atman E, Elhan AH, Gok H, Kucukdeveci AA. Does extracorporeal shock wave therapy decrease spasticity of ankle plantar flexor muscles in patients with stroke: A randomized controlled trial. Clin Rehabil. 2021 Oct;35(10):1442-1453. doi: 10.1177/02692155211011320. Epub 2021 Apr 28.

Reference Type BACKGROUND
PMID: 33906450 (View on PubMed)

Yang E, Lew HL, Ozcakar L, Wu CH. Recent Advances in the Treatment of Spasticity: Extracorporeal Shock Wave Therapy. J Clin Med. 2021 Oct 14;10(20):4723. doi: 10.3390/jcm10204723.

Reference Type BACKGROUND
PMID: 34682846 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

University of Health Sciences

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.